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Abstract
Introduction Gefitinib (Iressa, ZD 1839, AstraZeneca) blocks
the tyrosine kinase activity of the epidermal growth factor
receptor (EGFR) and inhibits proliferation of several human
cancer cell types including breast cancer. Phase II clinical trials
with gefitinib monotherapy showed an objective response of 9
to 19% in non-small-cell lung cancer patients and less than 10%
for breast cancer, and phase III results have indicated no benefit
of gefitinib in combination with chemotherapy over
chemotherapy alone. In order to improve the antineoplastic
activity of gefitinib, we investigated the effects of blocking the
signalling of the insulin-like growth factor 1 receptor (IGF-1R), a
tyrosine kinase with a crucial role in malignancy that is
coexpressed with EGFR in most human primary breast
carcinomas.
Methods AG1024 (an inhibitor of IGF-1R) was used with
gefitinib for treatment of MDA468, MDA231, SK-BR-3, and
MCF-7 breast cancer lines, which express similar levels of IGF-
1R but varying levels of EGFR. Proliferation assays, apoptosis
induction studies, and Western blot analyses were conducted
with cells treated with AG1024 and gefitinib as single agents
and in combination.
Results Gefitinib and AG1024 reduced proliferation in all lines
when used as single agents, and when used in combination
revealed an additive-to-synergistic effect on cell growth
inhibition. Flow cytometry measurements of cells stained with
annexin V-propidium iodide and cells stained for caspase-3
activation indicated that adding an IGF-1R-targeting strategy to
gefitinib results in higher levels of apoptosis than are achieved
with gefitinib alone. Gefitinib either reduced or completely
inhibited p42/p44 Erk kinase phosphorylation, depending on
the cell line, while Akt phosphorylation was reduced by a
combination of the two agents. Overexpression of IGF-1R in SK-
BR-3 cells was sufficient to cause a marked enhancement in
gefitinib resistance.
Conclusion These results indicate that IGF-1R signaling
reduces the antiproliferative effects of gefitinib in several breast
cancer cell lines, and that the addition of an anti-IGF-1R strategy
to gefitinib treatment may be more effective than a single-agent
approach.
Introduction
The signaling activity of receptor protein tyrosine kinases
(PTKs) is crucial to the control of apoptosis, differentiation,
and proliferation processes; consequently, dysfunction or
deregulation of these molecules can lead to uncontrolled
growth and neoplastic progression. The abnormal activation of
PTKs in the pathology of many cancers has called attention to
these receptors as potential targets for therapeutic interven-
tion [1-4]. Some neoplastic conditions arise from excessive
activity of a single PTK, for example Bcr-Abl in chronic myeloid
leukaemia [5], or c-kit or platelet-derived growth factor recep-
tor-α in gastrointestinal stromal cell tumours [6], and these
conditions are effectively treated using the PTK inhibitor
Gleevec (Imatinib mesylate) [7]. However, most cancers have
CI = combination index; EGFR = epidermal growth factor receptor; FACS = fluorescence-activated cell sorter; FBS = fetal bovine serum; FITC = 
fluorescein isothiocyanate; IC50 = inhibitory concentration 50%; IGF-1R = insulin like growth factor 1 receptor; PI3K = phosphatidylinositol 3-kinase; 
PTEN = phosphatase and tensin homolog; PTK = protein tyrosine kinase; VEGFR = vascular endothelial growth factor receptor.Breast Cancer Research    Vol 7 No 4    Camirand et al.
R571
complex biochemical causes and may involve dysfunction of
several PTKs as well as crosstalk between downstream sign-
aling pathways. One approach to address the multiplicity
problem involves cotargeting different PTKs [8-17], but for
maximal efficacy, the choice of PTKs to be simultaneously
blocked in any specific cancer type is crucial.
The epidermal growth factor receptor (EGFR, erbB1, or
HER1) is a 170-kDa member of the erbB family of PTKs, which
are transmembrane receptors with important roles in develop-
ment, differentiation, proliferation, and migration [18]. The acti-
vation of EGFR by ligand binding causes dimerization and
autophosphorylation of the receptor and subsequent recruit-
ment of downstream molecules, leading to mitogenic signaling
[19]. EGFR is overexpressed in a large subset of primary
breast carcinomas, and EGFR ligands such as TGF-α and
amphiregulin are found in 50 to 90% of primary breast carci-
nomas [20]. The co-occurrence of these sets of factors is
associated with poor prognosis and resistance to hormonal
therapy [21].
Several anti-EGFR molecules have been shown to cause neo-
plastic growth inhibition [22]. Among these, gefitinib (Iressa;
AstraZeneca) is an orally active synthetic anilinoquinazoline (4-
(3-chloro-4-fluroanilino)-7-methoxy-6-(3-morpholinopropoxy)
quinazoline) that inhibits EGFR but also has activity against
erbB2 and vascular endothelial growth factor receptor 2
(VEGFR-2) at 100-fold higher than those needed for EGFR
inhibition [23]. It has proved an effective inhibitor of prolifera-
tion in experimental human breast cancer cell systems, either
alone or in combination with other antineoplastic agents
[10,11,14,24-32]. Gefitinib as second- or third-line mono-
therapy in phase II trials of non-small-cell lung cancer patients
provided objective tumour response rates of 9 to 19%
[22,33,34]. A response rate of 10.8% was also seen in head
and neck cancer patients [35], but phase II trials in advanced
breast cancer patients showed partial response in fewer than
10% of patients [36-38]. Non-small-cell lung cancer phase III
trials where gefitinib was used in combination with traditional
chemotherapy (paclitaxel, gemcitabine, or cisplatin) showed
no added benefit of gefitinib to patients over chemotherapy
alone [39,40]. The acceptable safety profile of gefitinib was,
however, confirmed by these studies, and the results motivate
studies to determine if PTK cotargeting might improve the effi-
cacy of the drug.
A potential cotarget receptor in breast cancer is the insulin-like
growth factor 1 receptor (IGF-1R). In its mature form, IGF-1R
is a heterotetrameric receptor (two extracellular 125-kDa α
chains and two transmembrane 95-kDa β chains) that auto-
phosphorylates after ligand binding and activates several
downstream signaling routes, including the phosphatidylinosi-
tol 3-kinase (PI3K) and mitogen-activated protein kinase
(MAPK) pathways. Signaling through IGF-1R stimulates prolif-
eration, promotes angiogenesis and metastasis, and inhibits
apoptosis [41-45]. There is now abundant evidence indicating
that signaling through the IGF-1R pathway is important in
many cancers, including breast cancer [4,42,46-49], and
recent preclinical work has shown that IGF-1R could be used
as a successful cotarget with EGFR in primary human glioblas-
toma cells [13,50], with c-kit in small-cell lung cancer [15,17],
and with HER2/erbB2 in breast cancer cells [12,16]. AG1024
(3-bromo-5-t-butyl-4-hydroxy-benzylidenemalonitrile) is a syn-
thetic tyrphostin that inhibits ligand-stimulated IGF-1R auto-
phosphorylation in intact cells, with an inhibitory concentration
50% (IC50) of 7 µM and can affect the insulin receptor at 9- to
10-fold higher concentrations (IC50 57 µM) [51]. Tyrphostins
bind to the active site of receptors and modify its conformation
to prevent the substrate and ATP from binding [51]. Through
its anti-IGF-1R activity, AG1024 inhibits cell proliferation and
induces apoptosis in several cell systems, including non-small-
cell lung cancer [52], small-cell lung cancer [17], melanoma
[53], and breast cancer [54].
In this study, AG1024 and gefitinib were used to cotarget IGF-
1R and EGFR activity in several human breast cancer cell lines
that express IGF-1R similarly but present different levels of
EGFR. We show that combination treatment causes additivity
or synergy in growth inhibition and apoptosis induction, and
we speculate that adding an anti-IGF-1R strategy to gefitinib
treatment may be more effective than single-agent gefitinib
therapy.
Materials and methods
Chemicals and drugs
Gefitinib (ZD 1839, Iressa) was a gift from AstraZeneca (Mac-
clesfield, UK). AG1024 was purchased from Calbiochem-
EMD Biosciences (La Jolla, CA, USA).
Cell lines and proliferation assays
Breast cancer cell lines MCF-7, MDA468, MDA231, and SK-
BR-3 were obtained from ATCC (Manassas, VA, USA). Cells
were cultured at 37°C with 5% CO2 in RPMI 1640 (MCF-7) or
McCoy medium (all other cell lines) with 10% fetal bovine
serum (FBS) (InVitrogen, Gaithersburg, MD, USA), except in
growth inhibition assays, where the FBS supplement was
reduced to 1%. Cell proliferation was measured with the
Alamar Blue dye reduction method (Biosource International,
Camarillo, CA, USA). Growth tests were conducted with 104
cells/well in 200 µl media in 96-well plates, and three repli-
cates per dose combination were used for each experiment.
Experiments shown here are representative of three repeats.
Stock solutions of tyrphostin AG1024 and gefitinib were
made in dimethyl sulfoxide to 10 mM, stored at -20°C, and
diluted in medium containing 1% FBS just before use. The
concentration of dimethyl sulfoxide in the final culture was kept
below 0.2% (v/v). All procedures involving tyrphostins were
conducted in low light intensity.Available online http://breast-cancer-research.com/content/7/4/R570
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Flow cytometry for receptors
Medium was removed from breast cancer cells growing in
monolayers, and cells were collected by scraping in 1 ml 4°C
FACS (fluorescence-activated cell sorter) buffer (3% fetal
bovine serum, 0.02% NaN3 in PBS). Cells were centrifuged
and washed in FACS buffer; approximately 106 cells were
stained with phycoerythrin-conjugated anti-IGF-1R (BD
Pharmingen, San Diego, CA, USA), or with fluorescein-isothi-
ocyanate-conjugated (FITC-conjugated) anti-EGFR antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 30 min
at 4°C in the dark, washed twice in FACS, and resuspended
in the same buffer. Analysis was conducted for 20,000 cells
using a FACSCalibur flow cytometer (BD Biosciences, Burl-
ington, MA, USA) with CellQuest software (BD Biosciences
Immunocytometry Systems, Franklin Lakes, NJ, USA). Normal
mouse IgG1 (Santa Cruz Biotechnology) was used for isotype
determination. All tests were conducted in duplicate and the
experiments shown here are representative of two repeats.
Flow cytometry for apoptosis induction
Growth medium was removed from breast cancer cells grow-
ing in monolayers; adherent cells were briefly trypsinized,
detached, combined with floating cells from the original
growth medium, centrifuged, and washed twice with PBS.
Approximately 106 cells were stained for 30 min with annex-
inV–FITC and propidium iodide using the ApoTarget kit (Bio-
source International). Analysis was conducted on a
FACSCalibur flow cytometer using CellQuest software (see
receptor section, above). For quantification of caspase-3 acti-
vation, cells (approximately 0.5 × 106) were obtained as for
testing with annexinV and propidium iodide, but were washed
in media, resuspended in 150 µl media containing 10% FBS
and 0.5 µl Red-DEVD-FMK (Caspase-3 detection kit, Calbio-
chem-EMD Biosciences), and incubated for 30 min at 37°C in
a cell-culture incubator with 5% CO2. The stained cells were
centrifuged, washed twice with the wash buffer provided in the
kit, resuspended in 500 µl of the same buffer, and analyzed for
fluorescence on a FACSCalibur flow cytometer using Cel-
lQuest software. All apoptosis tests were conducted in dupli-
cate and results shown are representative of three
experiments.
Western blotting and immunoprecipitation
Cells growing in monolayers in 10-cm culture plates were
treated with various doses of AG1024, gefitinib, or vehicle for
24 or 72 hours, then lysed in nondenaturing buffer (1% Noni-
det NP-40, 20 mM TrisCl pH 8.0; 0.5 mM sodium orthovana-
date, pH 9.0; and proteinase inhibitors (Roche, Mannheim,
Germany)), and particulate material was removed by centrifu-
gation at 4°C. Samples (50 µg) of the supernatant were sep-
arated on 10% or 15% polyacrylamide gels. After transfer to
TransBlot nitrocellulose membranes (BioRad, Hercules, CA,
USA), the proteins were reacted overnight with the following
primary antibodies at 1:1,000 dilution: anti-Akt, anti-phospho-
Akt (Ser473), anti-Erk1/Erk2 (p44/42) anti-phospho-Erk1/
Erk2 (Thr202/Tyr204), and anti-EGFR (Cell Signalling Tech-
nologies, Beverly, MA, USA). Anti-phospho-EGFR (Tyr1173)
was from Upstate (Charlottesville, VA, USA). Blots were then
reacted for 1 hour with 1:2,000 horseradish-peroxidase-con-
jugated antirabbit immunoglobulin G (Pharmacia-Amersham,
Piscataway, NJ, USA). Tubulin 1:200 (Santa Cruz Biotechnol-
ogy) and antimouse immunoglobulin G (Pharmacia-Amer-
Figure 1
Surface expression of IGF-1R and EGFR in human breast cancer cell lines Surface expression of IGF-1R and EGFR in human breast cancer cell lines. Untreated cells were stained with phycoerythrin-conjugated anti-IGF-1R 
(insulin like growth factor-1 receptor) or with fluorescein-isothiocyanate-conjugated anti-EGFR (anti-epidermal growth factor receptor) antibody. 
Shaded peaks show flow cytometry analysis of the number of insulin-like growth factor 1 (top row) and epidermal growth factor (bottom row) recep-
tors on the surface of MDA468, MCF-7, MDA231, and SK-BR-3 human breast cancer cells. Outlined peak represents isotype control (normal 
mouse IgG1). Counts indicate number of events.Breast Cancer Research    Vol 7 No 4    Camirand et al.
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sham) were used to check evenness of loading. Membranes
were reacted with enhanced chemiluminescence (ECL) rea-
gents (Pharmacia-Amersham) and exposed to X-OMAT LS
film (Kodak, Rochester, NJ, USA). For immunoprecipitation,
500-µg samples of soluble protein in a final volume of 500 µl
were incubated with 10 µl antiphosphotyrosine monoclonal
antibody (BD Pharmingen, Mississauga, ON, Canada) with
rotation at 4°C overnight. A mixture (20 µl) of protein A and G+
Sepharose beads (Santa Cruz Biotechnology) was then
added, and the samples were rotated at 4°C for 1 hour. Beads
were collected by centrifugation, washed once with lysis
buffer, heated for 5 min at 95°C in SDS–PAGE loading buffer,
and separated by electrophoresis. Membranes after transfer
were reacted with an anti-IGF-1R β-subunit antibody (Santa
Cruz Biotechnology) and processed as above for enhanced
chemiluminescence detection. Western blot analyses were
repeated twice.
Statistical analysis
Statistical validity was evaluated using Student's t-test or the
Student Newmany–Keuls test for multiple pairwise compari-
sons of means with Statistical Analysis System software, ver-
sion 8 (SAS Institute, Cary, NC, USA), with P values ≤ 0.05
considered significant.
Figure 2
Inhibition of breast cancer cell growth by AG1024 and gefitinib singly and in combination Inhibition of breast cancer cell growth by AG1024 and gefitinib singly and in combination. (a) Cells in exponential stages of growth were exposed to 
increasing concentrations of inhibitors for 72 hours in media containing 1% fetal bovine serum. Triplicates were used for each dose combination for 
each experiment. (b) Proliferation combination index (CI) values were calculated using the classic isobologram equation [55] and indicate synergy 
(CI < 1) or additivity (CI approximately 1).Available online http://breast-cancer-research.com/content/7/4/R570
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Figure 3
Treatment with AG1024 enhances apoptotic effects of gefitinib Treatment with AG1024 enhances apoptotic effects of gefitinib. (a) Flow cytometric analysis of apoptosis in cells stained with annexin V and propid-
ium iodide after 72-hour treatment of breast cancer cells with AG1024 (AG), gefitinib (GE), or both. (b) Flow cytometric analysis of caspase-3 
induction by Red-DEVD-FMK fluorescence after 24-hour treatment of cells with AG1024, gefitinib, or both. Addition of AG1024 to gefitinib treat-
ment significantly enhanced apoptotic induction over levels achieved by gefitinib alone. Values on horizontal axes are concentrations (µM). *P < 
0.05.Breast Cancer Research    Vol 7 No 4    Camirand et al.
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Results
Surface expression of IGF-1R and EGFR in breast cancer 
cell lines
The breast cancer cell lines tested exhibit similar surface
expression of the IGF-1 receptor, but the number of EGF
receptors varied considerably, with MDA468 cells showing
very high expression, MDA231 intermediate levels, SK-BR-3
low expression, and MCF-7 no significant presence of EGFR
(Fig. 1).
Inhibition of IGF-1R signaling enhances the effect of 
gefitinib on the proliferation of breast cancer cell lines
In the culture conditions used here, proliferation IC50 values
(means ± standard deviations) for AG1024 were 3.5 µM ± 0.4
for MDA468; 3.5 µM ± 0.5 for MCF-7; 4.5 µM ± 0.4 for
MDA231; and 2.5 ± 0.4 for SK-BR-3 cells. The respective
IC50 values for gefitinib were 8.0 µM ± 1.0; 9.2 µM ± 2.3; 11.5
µM ± 3.0; and 6.5 µM ± 1.5.
The use of treatments combining AG1024 and gefitinib
revealed that the cotargeting approach achieved a greater
growth inhibition (Fig. 2a). Combination index (CI) values cal-
culated according to the classic isobologram equation [55]
evaluate the interactions between agents as additive (CI
approximately 1), antagonistic (CI >1), or synergistic (CI <1).
The results (Fig. 2b) indicate synergy (for MDA468) or additiv-
ity (other cell lines) of interaction between AG1024 and
gefitinib.
Adding an anti-IGF-1R strategy to gefitinib treatment 
increases levels of apoptosis
Flow cytometric analyses of breast cancer cells treated with
AG1024, gefitinib, or both, and stained with annexinV and pro-
pidium iodide (cells treated for 3 days) or with red–DEVD–
FMK for caspase-3 activation (cells treated for 1 day) are
shown in Fig. 3a,b. In all cell lines, and for both methods of
detecting apoptosis, conditions were found where addition of
AG1024 significantly increased apoptosis levels over those
seen with gefitinib alone.
Effect of treatment with AG1024 or gefitinib on protein 
and phosphorylation levels of Akt and p44/p42 Erk 
kinases
After 24 hours of treatment, gefitinib decreased the levels of
Erk phosphorylation in most cell lines, and completely elimi-
nated Erk phosphorylation in MDA468 (Fig. 4). In contrast, the
phosphorylation levels of Akt were reduced by the combina-
tion of the two agents. Erk and Akt protein levels were not
affected by the 24-hour treatments. Tubulin levels confirmed
equal loading (not shown).
Overexpression of IGF-1R greatly reduces sensitivity to 
gefitinib
SK-BR-3 cells transfected to overexpress the IGF-1 receptor
(SK-BR-3-IR) [12] were tested for sensitivity to gefitinib. Fig-
ure 5a illustrates the high IGF-1R expression levels observed
by flow cytometry in SK-BR-3-IR cells compared with the lev-
els in the SK-BR-3 parental line shown in Fig. 1. Increased
expression of IGF-1R caused a very marked enhancement in
resistance to the growth-inhibitory effects of gefitinib (Fig. 5b).
Effect of treatment with AG1024 or gefitinib on tyrosine 
phosphorylation of IGF-1R and EGFR
An example of the effect of AG1024, gefitinib, or both (24-
hour treatment) on the phosphorylation levels of IGF-1 and
EGF receptors in 1% serum conditions is illustrated in Fig. 6.
In MCF-7 cells (left), AG1024 at 2.5 µM eliminated phospho-
rylation of IGF-1R, while gefitinib did not affect the phosphor-
ylation state of IGF-1R. EGFR phosphorylation levels were
decreased by gefitinib, but only slightly affected by AG1024
treatment (MDA468 cells, Fig. 6, right). Protein levels for both
receptors were unaffected by treatment in the conditions used
here.
Discussion
Several reports have suggested that cotargeting protein tyro-
sine kinases results in substantial enhancement of growth inhi-
bition [8-17]. In the present study, the choice of the IGF-1
receptor as cotarget is based on the knowledge that this
receptor drives important cell survival pathways [41-45] and
Figure 4
Effect of treatment on Erk and Akt kinases phosphorylation and protein levels Effect of treatment on Erk and Akt kinases phosphorylation and protein levels. Western blot analysis showing phosphorylation (P) (top) and protein 
(bottom) levels of Akt and p44/p42 Erk kinases in cells treated for 24 hours with AG1024 (AG), gefitinib (GE), or both.Available online http://breast-cancer-research.com/content/7/4/R570
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that reduction of its antiapoptotic effects increases the effi-
cacy of treatments targeting several other neoplasia-related
PTKs [12,13,15-17]. The results presented here show the
effects of adding an anti-IGF-1R strategy to gefitinib treatment
in human breast cancer cell lines chosen for their similar
expression of IGF-1R but their different EGFR levels (Fig. 1).
Gefitinib and AG1024 used as single agents show antiprolif-
erative activity on all cell lines tested, and their combination
produces an additive-to-synergistic enhancement of growth
inhibition (Fig. 2a,b). The mechanism of action on cancer cells
of EGFR blockers such as AG 1478, mAb225, and gefitinib is
generally cytostatic and proceeds via a G0/G1 arrest [56].
Most breast cancer cells are growth-arrested by gefitinib, but
only a subset shows induction of apoptosis (cytotoxic effect)
[31], and high doses of the drug are needed to induce apop-
tosis in normal mammary epithelial cells and primary cultures
of mammary carcinoma cells [24]. Blocking the antiapoptotic
IGF-1R pathway with AG1024 improves apoptosis induction
over the level due to treatment with gefitinib alone (Fig. 3). All
the cell lines tested exhibited this effect, regardless of the lev-
els of expression of EGFR. In fact, the growth-inhibitory effect
of gefitinib has been reported to be independent of the levels
of expression of EGFR in human breast cancer cells [10,24-
26,31] and other cancer cell lines [57]. As the EGFR expres-
sion level is not a good predictor of gefitinib sensitivity [58],
EGFR expression status in tumours cannot be used to exclude
patients from gefitinib trials [59]. It has been shown that the
presence of somatic mutations in the EGFR gene in lung can-
cer samples correlates with sensitivity to gefitinib [60,61].
However, even in the absence of detectable EGFR (as in
MCF-7 cells: our results, Fig. 1, and [10]), gefitinib and
AG1024 still have additive capability, raising the possiblity of
a non-EGFR-specific gefitinib effect that can be enhanced by
the anti-IGF-1R agent.
Western blot analysis (Fig. 4) showed that after a 24-hour
treatment, gefitinib affects phosphorylation levels of p44/p42
Erk and Akt kinases, but that combination treatment with the
anti-IGF-1R agent causes a further reduction in levels of Akt
phosphorylation. The effect is particularly visible for MDA468
cells, which probably reflects the fact that these cells show a
synergistic rather than additive growth reduction pattern. Inter-
estingly, MDA468 cells (PTEN-null) (phosphatase-and-tensin-
homolog-null) have been reported to show a relative resist-
ance to gefitinib that can be reversed through the use of the
PI3K inhibitor LY294002 [62] or PTEN reconstitution [30],
pointing to a crucial role for receptors that signal through the
PI3K cascade, such as IGF-1R. MDA468 cells are also the
most sensitive to gefitinib inhibition of Erk phosphorylation. In
longer treatments (not shown), the levels of protein expression
for Akt and Erk are decreased by AG1024 or by the combina-
tion of agents. AG1024 treatment has been reported to
decrease the expression of several proteins known as regula-
tors of apoptosis and the cell cycle [53,54], and the inhibitor
may therefore also provide a longer-term inhibitory effect by
mechanisms involving protein degradation.
Figure 5
Overexpression of IGF-1R results in enhanced resistance to gefitinib  antiproliferation activity Overexpression of IGF-1R results in enhanced resistance to gefitinib 
antiproliferation activity. (a) Flow cytometry estimation of surface 
expression levels of epidermal growth factor 1 receptor (IGF-1R) 
(shaded peak) in the SK-BR-3-IR line, which differs from its parental 
line, SK-BR-3, only by the transfected IGF-1R gene [12]. Outlined peak 
is normal mouse IgG1 isotype. Counts indicate number of events. (b) 
Effect of a 72-hour treatment with gefitinib alone on the proliferation of 
SK-BR-3 and SK-BR-3-IR cells. Triplicates were used for each dose.Breast Cancer Research    Vol 7 No 4    Camirand et al.
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An important point, illustrated in Fig. 5, is that overexpression
of the IGF-1 receptor results in increased resistance to gefit-
inib. This observation implies that one way in which breast can-
cer cells resist gefitinib is through the signaling activity of IGF-
1R. Since gefitinib does not affect phosphorylation of the IGF-
1 receptor (Fig. 6 and [63]), our results suggest that the antia-
poptotic pathways driven by IGF-1 signalling should be
targeted in order to optimize the antineoplastic effects of gefit-
inib. While our model system involves increased IGF-1R activ-
ity due to receptor overexpression, it must be noted that
increased IGF-1R signaling in clinical breast cancer might also
arise from mechanisms involving abnormally high IGF-2
expression or from derangements in IGF-binding protein phys-
iology [42].
The findings described here suggest that the antineoplastic
effects of gefitinib may be significantly underestimated if exam-
ined only under conditions in which IGF-IR is fully functional.
Several anti-IGF-1R compounds are now being developed for
clinical evaluation [64-67], and it should soon be feasible to
conduct trials to test the hypothesis that the efficacy of gefit-
inib treatments is enhanced by IGF-1R targeting. The data pre-
sented here support further research into breast cancer
therapeutic strategies combining gefitinib with anti-IGF-1R
agents.
Conclusion
In several human breast cancer cell lines, addition of the IGF-
1R inhibitor AG1024 to gefitinib reduced cell proliferation in
an additive or synergistic fashion and enhanced the induction
of apoptosis over levels achieved by gefitinib alone. This effect
was independent of levels of expression of the EGF receptor.
Overexpression of IGF-1R in SK-BR-3 cells was sufficient to
cause a marked enhancement in gefitinib resistance. IGF-1R
signaling can therefore limit the antiproliferative effects of
gefitinib in vitro, and we speculate that for a subset of human
breast cancers, adding an anti-IGF-1R strategy to gefitinib
treatment may be more effective than a single-agent approach.
Competing interests
The author(s) declare that they have no competing interests.
Authors' contributions
Anne Camirand: study design, data collection, statistical anal-
ysis, data interpretation, manuscript preparation, literature
search and funds collection. Mahvash Zakikhani: data collec-
tion, statistical analysis, data interpretation, manuscript prepa-
ration, literature search. Fiona Young: data collection. Michael
Pollak: study design, funds collection.
All authors read and approved the final manuscript.
Acknowledgements
This work was supported by a grant to MP and AC from the Susan G 
Komen Foundation for Breast Cancer Research. Gefitinib was a gift 
from AstraZeneca (Macclesfield, UK).
References
1. Arteaga CL, Moulder SL, Yakes FM: HER (erbB) tyrosine kinase
inhibitors in the treatment of breast cancer. Semin Oncol 2002,
29:4-10.
2. Shawver LK, Slamon D, Ullrich A: Smart drugs: Tyrosine kinase
inhibitors in cancer therapy. Cancer Cell 2002, 1:117-123.
3. Dancey J, Sausville EA: Issues and progress with protein kinase
inhibitors for cancer treatment.  Nat Rev Drug Discov 2003,
2:296-313.
4. Surmacz E: Growth factor receptors as therapeutic targets:
strategies to inhibit the insulin-like growth factor-I receptor.
Oncogene 2003, 22:6589-6597.
5. Melo JV: The diversity of BCR-ABL fusion proteins and their
relationship to leukemia phenotype.  Blood 1996,
88:2375-2384.
6. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen C-J,
Joseph N, Singer S, Griffith DJ, Haley A, Town A, et al.: PDGFRA
activating mutations in gastrointestinal stromal tumors. Sci-
ence 2003, 299:708-710.
7. Druker BL, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM,
Lydon NB, Kantardjian H, Capdeville R, Ohno-Jones S, et al.: Effi-
cacy and safety of a specific inhibitor of the Bcr-Abl tyrosine
kinase in chronic myeloid leukemia. New Engl J Med 2001,
344:1031-1037.
8. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J: Apoptosis
induced by an anti-EGFR monoclonal antibody in human color-
ectal carcinoma cell line and its delay by insulin. J Clin Invest
1995, 95:1897-1905.
9. Ye D, Mendelsohn J, Fan Z: Augmentation of a humanized anti-
HER2 mAb 4D5 induced growth inhibition by a human-mouse
chimeric anti-EGF receptor mAb C225.  Oncogene 1999,
18:731-738.
10. Moasser MM, Basso A, Averbuch SD, Rosen N: The tyrosine
kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven sign-
aling and suppresses the growth of HER2-overexpressing
tumor cells. Cancer Res 2001, 61:7184-7188.
Figure 6
Single agent treatment effect on tyrosine phosphorylation (P; top) and protein expression of receptors Single agent treatment effect on tyrosine phosphorylation (P; top) and protein expression of receptors. Western blot showing phosphorylation (P, 
top) and receptor protein levels (bottom). MCF-7 cells were used for detection of phosphorylation of the insulin like growth factor 1 receptor (IGF-
1R) and MDA468 cells, for phosphorylation analysis of the epidermal growth factor receptor (EGFR). AG, AG1024; GE, gefitinib.Available online http://breast-cancer-research.com/content/7/4/R570
R578
11. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF,
Arteaga CL: Epidermal growth factor receptor (HER1) tyrosine
kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-
overexpressing breast cancer cells in vitro and in vivo. Cancer
Res 2001, 61:8887-8895.
12. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M: Insulin-like growth
factor-I receptor signaling and resistance to trastuzumab
(Herceptin). J Natl Cancer Inst 2001, 93:1852-1857.
13. Chakravarti A, Loeffler JS, Dyson NJ: Insulin-like growth factor
receptor I mediates resistance to anti-epidermal growth factor
receptor therapy in primary human glioblastoma cells through
continued activation of phosphoinositide 3-kinase signaling.
Cancer Res 2002, 62:200-207.
14. Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciar-
diello F, Gianni L, Salomon DS, Menard S: Cooperative inhibitory
effect of ZD1839 (Iressa) in combination with trastuzumab
(Herceptin) on human breast cancer cell growth. Ann Oncol
2002, 13:65-72.
15. Warshamana-Grene GS, Litz J, Buchdunger E, Hofmann F, Gar-
cia-Echeverria C, Krystal GW: The insulin-like growth factor-I
(IGF-I) receptor kinase inhibitor NVP-ADW742, in combination
with STI571, delineates a spectrum of dependence of small
cell lung cancer on IGF-I and stem cell factor signalling. Mol
Cancer Ther 2004, 3:527-535.
16. Camirand A, Lu Y, Pollak M: Co-targeting HER2/ErbB2 and
insulin-like growth factor-1 receptors causes synergistic inhi-
bition of growth in HER2-overexpressing breast cancer cells.
Med Sci Monit 2002, 8:BR521-BR526.
17. Camirand A, Pollak M: Co-targeting IGF-1R and c-kit: synergis-
tic inhibition of proliferation and induction of apoptosis in H
209 small cell lung cancer cells.  Br J Cancer 2004,
90:1825-1829.
18. Rusch V, Mendelsohn J, Dmitrovsky E: The epidermal growth
factor receptor and its ligands as therapeutic targets in human
tumors. Cytokine Growth Factor Rev 1996, 7:133-141.
19. Yarden Y: The EGFR family and its ligands in human cancer:
signalling mechanisms and therapeutics opportunities. Eur J
Cancer 2001, 37:S3-S8.
20. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal
growth factor-related peptides and their receptors in human
malignancies. Crit Rev Oncol Hematol 1995, 19:183-232.
21. Woodburn JR: The epidermal growth factor receptor and its
inhibition in cancer therapy. Pharmacol Ther 1999, 82:241-250.
22. Blackledge G, Averbuch S: Gefitinib ('Iressa', ZD 1839) and new
epidermal growth factor receptor inhibitors. Br J Cancer 2004,
90:566-572.
23. Ranson M: ZD1839 (Iressa): for more than just non-small cell
lung cancer. Oncologist 2002, 7:16-24.
24. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De
Placido S, Bianco AR, Tortora G: Antitumor effect and potentia-
tion of cytotoxic drugs activity in human cancer cells by ZD-
1839 (Iressa), an epidermal growth factor receptor-selective
tyrosine kinase inhibitor. Clin Cancer Res 2000, 6:2053-2063.
25. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuc-
cato S, De Placido S, Raffaele Bianco A, Tortora G: Inhibition of
growth factor production and angiogenesis in human cancer
cells by ZD1839 (Iressa)1, a selective epidermal growth factor
receptor tyrosine kinase inhibitor.  Clinical Cancer Research
2001, 7:1459-1465.
26. Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ: ZD1839
(Iressa), a novel epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, potently inhibits the growth of EGFR-
positive cancer cell lines with or without erbB2
overexpression. Int J Cancer 2001, 94:774-782.
27. Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D,
McClelland RA, Jones HE, Wakeling AE, Gee JMW: Modulation
of epidermal growth factor receptor in endocrine-resistant,
oestrogen receptor-positive breast cancer.  Endocr Relat
Cancer 2001, 8:175-182.
28. Morris C: The role of EGFR-directed therapy in the treatment of
breast cancer. Breast Cancer Res Treat 2002, 75:S51-S55.
29. Arteaga C: Targeting HER1/EGFR: a molecular approach to
cancer therapy. Semin Oncol 2003, 30 (3 Suppl 7):3-14.
30. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsuru-
tani J, Dennis PA, Mills GB, Arteaga CL: Loss of PTEN/MMAC1/
TEP in EGF receptor-expressing tumor cells counteracts the
antitumor action of EGFR tyrosine kinase inhibitors. Oncogene
2003, 22:2812-2822.
31. Campiglio M, Locatelli A, Olgiati C, Normanno N, Somenzi G,
Vigano L, Fumagalli M, Menard S, Gianni L: Inhibition of prolifer-
ation and induction of apoptosis in breast cancer cells by the
epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor ZD1839 ('Iressa') is independent of EGFR expression
level. J Cell Physiol 2004, 198:259-268.
32. Gee JMW, Harper ME, Hutcheson IR, Madden TA, Barrow D,
Knowlden JM, McClelland RA, Jordan N, Wakeling AE, Nichelson
RI: The antiepidermal growth factor receptor agent gefitinib
(ZD1839/Iressa) inproves antihormone response and pre-
vents development of resistance in breast cancer in vitro.
Endocrinology 2003, 144:5105-5117.
33. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP,
Schiller JH, Kelly K, Spiridonidis H, Sandler A, et al.: Efficacy of
gefitinib, an inhibitor of the epidermal growth factor receptor
tyrosine kinase, in symptomatic patients with non-small cell
lung cancer, a randomized trial. JAMA 2003, 290:2149-2158.
34. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douil-
lard J-Y, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, et al.:
Multi-institutional randomized phase II trial of gefitinib for pre-
viously treated patients with adanced non-small-cell lung
cancer. J Clin Oncol 2003, 21:2237-2246.
35. Cohen EEW, Rosen F, Stadler WM, Recant W, Stenson K, Huo D,
Vokes EE: Phase II trial of ZD1839 in recurrent or metastatic
squamous cell carcinoma of the head and neck. J Clin Oncol
2003, 21:1980-1987.
36. Baselga J, Albanell J, Ruiz A, Lluch A, Gascon S, Guillen V,
Sauleda S, Averbuch S, Rojo F: Phase II and tumor pharmaco-
dynamic study of gefinitib (ZD 1839) in patients with advanced
breast cancer [abstract].  Proc Am Soc Clin Oncol 2003,
22:S24.
37. Robertson JFR, Gutteridge E, Cheung KL, Owers R, Koehler M,
Hamilton L, Gee J, Nicholson RI: Gefitinib (ZD 1839) is active in
acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-
positive and ER-negative breast cancer: Results from a phase
II study [abstract]. Proc Am Soc Clin Oncol 2003, 22:S23.
38. von Minckwitz G, Jonat W, Beckmann M, du Bois A, Kleeberg U,
Kühnle H, Kettner E, Hilfrich J, Torode J, Schneider A: A multi-
center phase II trial to evaluate gefitinib ('Iressa', ZD1839)
(500 mg/day) in patients with metastatic breast cancer after
previous chemotherapy treatment [abstract]. Proceedings of
the 12th European Conference on Clinical Oncology, Copenha-
gen, Denmark . 21–25 sept. 2003, abstract 437
39. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller
V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, et al.: Gefit-
inib in combination with gemcitabine and cisplatin in advanced
non-small-cell lung cancer: a phase III trial – INTACT 1. J Clin
Oncol 2004, 22:777-784.
40. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Mane-
gold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, et al.: Gefitinib in
combination with paclitaxel and carboplatin in advanced non-
small-cell lung cancer: a phase III trial – INTACT2. J Clin Oncol
2004, 22:785-794.
41. Pollak M: Insulin-like growth factor physiology and cancer risk.
Eur J Cancer 2000, 36:1224-1228.
42. Pollak M, Schernhammer ES, Hankinson SE: Insulin-like growth
factors and neoplasia. Nat Rev Cancer 2004, 4:505-518.
43. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE: The
effects of insulin-like growth factors on tumorigenesis and
neoplastic growth. Endocr Rev 2000, 21:215-244.
44. Yu H, Rohan T: Role of the insulin-like growth factor family in
cancer development and progression. J Natl Cancer Inst 2000,
92:1472-1489.
45. Wang Y, Sun Y: Insulin-like growth factor receptor-1 as an anti-
cancer target: blocking transformation and inducing
apoptosis. Curr Cancer Drug Targets 2002, 2:191-207.
46. Werner H, LeRoith D: The role of the insulin-like growth factor
system in human cancer. Adv Cancer Res 1996, 68:183-223.
47. Dunn SE, Ehrlich M, Sharp NJ, Reiss K, Solomon G, Hawkins R,
Baserga R, Barrett JC: A dominant negative mutant of the insu-
lin-like growth factor-I receptor inhibits the adhesion, invasion,
and metastasis of breast cancer.  Cancer Res 1998,
58:3353-3361.Breast Cancer Research    Vol 7 No 4    Camirand et al.
R579
48. Wood TL, Yee D: Introduction: IGFs and IGFBPs in the normal
mammary gland and in breast cancer. J Mammary Gland Biol
Neoplasia 2000, 5:1-5.
49. Yee D: The insulin-like growth factor system as a target in
breast cancer. Semin Oncol 2002, 29:86-95.
50. Steinbach JP, Eisenmann C, Klumpp A, Weller M: Co-inhibition of
epidermal growth factor receptor and type 1 insulin-like
growth factor receptor synergistically sensitizes human malig-
nant glioma cells to CD95L-induced apoptosis. Biochem Bio-
phys Res Commun 2004, 321:524-530.
51. Parrizas M, Gazit A, Levitzki A, Wertheimer E, and LeRoith D: Spe-
cific inhibition of insulin-like growth factor-I and insulin recep-
tor tyrosine kinase activity and biological function of
tyrphostins. Endocrinology 1997, 138:1427-1433.
52. Hurbin A, Dubrez L, Coll JL, Favrot MC: Inhibition of apoptosis by
amphiregulin via an insulin-like growth factor-1 receptor-
dependent pathway in non-small cell lung cancer cell lines. J
Biol Chem 2002, 277:49127-49133.
53. von Willebrand M, Zacksenhaus E, Cheng E, Glazer P, Halaban R:
The tyrphostin AG1024 accelerates the degradation of phos-
phorylated forms of retinoblastoma protein (pRb) and restores
pRb tumor suppressive function in melanoma cells. Cancer
Res 2003, 63:1420-1429.
54. Wen B, Deutsch E, Marangoni E, Frascona V, Maggiorella L,
Abdulkarim B, Chavaudra N, Bourhis J: Tyrphostin AG 1024 mod-
ulates radiosensitivity in human breast cancer cells.  Br J
Cancer 2001, 85:2017-2021.
55. Berenbaum MC: Criteria for analyzing inetactions between bio-
logically active agents. Adv Cancer Res 1981, 35:269-335.
56. Busse D, Doughty RS, Ramsey TT, Russel WE, Price JO, Flanagan
WM, Shawver LK, Arteaga CL: Reversible G(1) arrest induced
by inhibition of the epidermal growth factor receptor tyrosine
kinase requires up-regulation of p27(KIP1) independent of
MAPK activity. J Biol Chem 2000, 275:6987-6995.
57. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG: Efficacy
of cytotoxic agents against human tumor xenografts is mark-
edly enhanced by coadministration of ZD1839 (Iressa), an
inhibitor of EGFR tyrosine kinase.  Clin Cancer Res 2000,
6:4885-4892.
58. Bailey LR, Janas M, Schmidt K, Bindslev N, Wolf M, Grous J, Askaa
J, Herbst R, Johnson DH, Giacone G: Evaluation of epidermal
growth factor receptor (EGFR) as a predictive marker in
patients with non-small-cell lung cancer (NSCLC) receiving
first-line gefitinib combined with platinum-based chemother-
apy [abstract]. J Clin Oncol 2004, 22:S7013.
59. Arteaga C: Epidermal growth factor receptor dependence in
human tumors: more than just expression? Oncologist 2002,
7:31-39.
60. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Her-
man P, Kaye FJ, Lindeman N, Boggon TJ, et al.: EGFR mutations
in lung cancer: correlation with clinical response to gefitinib
therapy. Science 2004, 304:1497-1500.
61. Lynch TH, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA,
Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et
al.: Activating mutations in the epidermal growth factor recep-
tor underlying responsiveness of non-small-cell lung cancer to
Gefitinib. N Engl J Med 2004, 350:2129-2139.
62. She QB, Solit D, Basso A, Moasser MM: Resistance to Gefitinib
in PTEN-null HER-overexpressing tumor cells can be over-
come through restoration of PTEN function or pharmacologic
modulation of constitutive phosphatidylinositol 3'-kinase/Akt
pathway signaling.  Clinical Cancer Research 2003,
9:4340-4346.
63. Gilmore AP, Valentijn AJ, Wang P, Ranger AM, Bundred N, O'Hare
MJ, Wakeling A, Korsmeyer SJ, Streuli CH: Activation of BAD by
therapeutic inhibition of epidermal growth factor receptor and
transactivation by isulin-like growth factor receptor.  J Biol
Chem 2002, 277:27643-27650.
64. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors
KM, Zhou X-M, Blattler WA, Chittenden T, Singh R: An anti-insu-
lin-like growth factor-I receptor antibody that is a potent inhib-
itor of cancer cell proliferation.  Cancer Res 2003,
63:5073-5083.
65. Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zim-
mermann J, Gao J, Brueggen J, Capraro H-G, Cozens R, Evans
DB, Fabbro D, Furet P, Graus-Porta D, Liebetanz J, Martiny-Baron
G, Ruetz S, Hofmann F: In vivo anti-tumor activity of NVP-
AEW541 – A novel, potent and selective inhibitor of the IGF-IR
kinase. Cancer Cell 2004, 5:231-239.
66. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringar-
pure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Liber-
mann TA, et al.:  Inhibition of the insulin-like growth factor
receptor-1 tyrosine kinase activity as a therapeutic strategy for
multiple myeloma, other hematologic malignancies, and solid
tumors. Cancer Cell 2004, 5:221-230.
67. Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, Haeuw JF,
Corvaia NA: A ecombinant humanized anti-insulin-like growth
factor receptor type I antibody (h7C10) enhances the antitu-
mor activity of vinorelbine and anti-epidermal growth factor
receptor therapy against human cancer xenographs.  Int J
Cancer 2005, 113:316-328.